Aspirin therapy's ability to reduce the risk of colorectal cancer, an association seen in a large number of studies, appears to depend on the drug's inhibition of the COX-2 enzyme, the action that also underlies aspirin's usefulness for treating pain and inflammation.
The Harvard University Center for AIDS Research, in collaboration with the Ragon Institute of MGH, MIT and Harvard, and the Clinical and Translational Epidemiology Unit at MGH, is sponsoring a week-long workshop focused exclusively on computational approaches to metagenomic analysis.
Regular use of aspirin after colorectal cancer diagnosis may reduce the risk of cancer death, report investigators from Massachusetts General Hospital, Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs may be limited to individuals already at risk because of elevations in a specific inflammatory factor in the blood.
A new study finds that colonoscopy appears to reduce the risk of developing or dying from colorectal cancer more powerfully than does sigmoidoscopy, a similar procedure that examines only a portion of the colon. The investigation also identifies molecular features that may help explain tumors that are diagnosed despite an individual's having recently undergone colonoscopy.
Researchers from MGH, Dana-Farber Cancer Institute and Case Western Reserve School of Medicine have shown that aspirin’s previous reported ability to reduce the risk of colorectal cancer applies only to individuals with high levels of a specific gene product in their colons.